General Information
Drug ID
DR00112
Drug Name
Irinotecan
Synonyms
(+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Biotecan; Biotecan (TN); CP0; Campto (TN); Camptosar; Camptosar (TN); Camptosar, Campto, CPT-11, Irinotecan; IRINOTECAN HYDROCHLORIDE Trihydrate; IRINOTECAN, CPT-11; Irinotecan (INN); Irinotecan (TOPO1 inhibitor); Irinotecan Hcl; Irinotecan [INN:BAN]; Irinotecan hydrochloride; Irinotecanum; Irinotecanum [INN-Latin]
Drug Type
Small molecular drug
Indication Colorectal cancer [ICD11: 2B91] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=60838"></iframe>
3D MOL 2D MOL
Formula
C33H38N4O6
Canonical SMILES
CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)C5(CC)O)OC(=O)N6CCC(CC6)N7CCCCC7
InChI
InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
InChIKey
UWKQSNNFCGGAFS-XIFFEERXSA-N
CAS Number
CAS 100286-90-6
Pharmaceutical Properties Molecular Weight 586.689 Topological Polar Surface Area 113
Heavy Atom Count 43 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
PubChem CID
60838
PubChem SID
103169165 , 104020044 , 104253165 , 104321776 , 11409441 , 117623718 , 118049657 , 124757074 , 124893595 , 125163878 , 126630981 , 126650121 , 126663759 , 129430288 , 134337937 , 134338553 , 135032920 , 136342503 , 137001856 , 142371089 , 143493285 , 143493286 , 144116083 , 14764625 , 14911520 , 152034388 , 152240238 , 43118176 , 46393294 , 46505871 , 47811029 , 48427687 , 49835834 , 49894524 , 50422254 , 51090967 , 53788707 , 56312891 , 56314523 , 57288560 , 57314141 , 6436484 , 645391 , 7886725 , 7979640 , 81092817 , 8187089 , 85789488 , 92711320 , 96024776
ChEBI ID
ChEBI:80630
TTD Drug ID
D07HOB
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [5]
MRP5 Transporter Info Multidrug resistance-associated protein 5 Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP2 Transporter Info Km = 48.9 microM Bile canalicular membrane vesicles-MRP2 [7]
MRP2 Transporter Info Km = 90.8 microM Madin-Darby canine kidney cells (MDCKII)-MRP2 [4]
P-GP Transporter Info Km = 116.1 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [4]
P-GP Transporter Info Km = 45.5 microM Madin-Darby canine kidney cells (MDCKII)-MDR1 [4]
References
1 Irinotecan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
3 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
4 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
5 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
6 Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
7 Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.